A putative class-action suit in New Jersey’s federal court accuses the maker of a cancer-treatment drug of cornering the oncology clinic market with an anti-competitive tying arrangement and pricing scheme.

According to the suit, Amgen Inc. of Thousand Oaks, Calif., requires oncology clinics to buy Aranesp, a red blood cell stimulant, if they want better prices for the company’s two white blood cell stimulants, Neulasta and Neupogen. The two drugs hold 98 percent of the market in sales to oncology clinics.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]